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ABSTRACT: Breast cancer resistance protein (BCRP) and
multidrug resistance-associated protein 2 (MRP2) are
members of the ATP binding cassette (ABC) transporter
family located in the canalicular membrane of hepatocytes that
mediate biliary excretion of many drugs and endogenous
compounds. BCRP and MRP2 have overlapping substrate
profiles. Predicting drug disposition in the setting of altered
transport function has important clinical significance. This
investigation was designed to establish an in vitro model
system to evaluate the impact of impaired Mrp2 and Bcrp
function on hepatobiliary drug disposition. To achieve Bcrp
knockdown by RNA interference (RNAi), sandwich-cultured
hepatocytes (SCH) from Mrp2-deficient (TR−) and wild-type (WT) rats were infected with adenoviral vectors to express
shRNA targeting Bcrp (Ad-siBcrp) at multiplicity of infection (MOI) of 1−10. MOI of 5 was identified as optimal. At MOI of 5,
viral infection as well as WT or TR− status was statistically significant predictors of the rosuvastatin (RSV) biliary excretion index
(BEI), consistent with the known role of Bcrp and Mrp2 in the biliary excretion of RSV in vivo in rats. Relative to WT rat SCH,
marginal mean BEI (%) of RSV in TR− rat SCH decreased by 28.6 (95% CI: 5.8−51.3). Ad-siBcrp decreased marginal mean BEI
(%) of RSV by 13.3 (7.5−9.1) relative to SCH infected with adenoviral vectors expressing a nontargeting shRNA (Ad-siNT).
The BEI of RSV was almost ablated in TR− rat SCH with Bcrp knockdown (5.9 ± 3.0%) compared to Ad-siNT-infected WT rat
SCH (45.4 ± 6.6%). These results demonstrated the feasibility of Bcrp knockdown in TR− rat SCH as an in vitro system to assess
the impact of impaired Bcrp and Mrp2 function. At MOI of 5, viral infection had minimal effects on RSV total accumulation, but
significantly decreased marginal mean taurocholate total accumulation (pmol/mg of protein) and BEI (%) by 9.9 (7.0−12.8) and
7.5 (3.7−11.3), respectively, relative to noninfected SCH. These findings may be due to off-target effects on hepatic bile acid
transporters, even though no changes in protein expression levels of the hepatic bile acid transporters were observed. This study
established a strategy for optimization of the knockdown system, and demonstrated the potential use of RNAi in SCH as an in
vitro tool to predict altered hepatobiliary drug disposition when canalicular transporters are impaired.
KEYWORDS: breast cancer resistance protein (BCRP/Bcrp), multidrug resistance-associated protein 2 (MRP2/Mrp2),
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■ INTRODUCTION
Hepatocytes are polarized cells with distinct apical and
basolateral domains. Transport proteins on the apical membrane
are responsible for excretion of compounds into the bile
canaliculus, whereas basolateral transport proteins mediate influx
into hepatocytes and efflux back to sinusoidal blood. Hepatic
canalicular and basolateral transport proteins play important
roles in regulating the pharmacologic and toxicologic effects of
many drugs by mediating hepatocellular exposure. Breast cancer
resistance protein (BCRP), a member of the ATP-binding
cassette (ABC) transporter family, is a half-transport protein that
forms a functional homodimer or oligomer.1,2 BCRP is highly
expressed in the canalicular membrane of hepatocytes as well as
in the intestine, breast, and placenta.3 BCRP substrates include
glucuronide and sulfate conjugates [e.g., estrone-sulfate,
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estradiol-17β-D-glucuronide (E217G), SN-38 glucuronide],
anticancer drugs (e.g., irinotecan, SN-38, methotrexate, daunor-
ubicin, doxorubicin), and some statins [e.g., pitavastatin,
rosuvastatin (RSV)].4−9 The pharmacokinetics and pharmaco-
dynamics of these drugs may be affected by modulation of BCRP
expression and/or function resulting from genetic poly-
morphisms or drug−drug interactions (DDIs).
Multidrug resistance-associated protein 2 (MRP2) is another
member of the ABC transporter family that is expressed in the
canalicular membrane of hepatocytes. Many drugs are substrates
for both BCRP and MRP2 including RSV, methotrexate,
doxorubicin, SN-38, and SN-38 glucuronide. Overlapping
substrate specificity can make it challenging to predict the
impact of altered function of one or more transport proteins on
the hepatic and systemic exposure of substrates. A significant
change in drug exposure is expected following loss-of-function of
one or more transport pathways when clearance by that
particular pathway (apical or basolateral) exceeds 50% of total
clearance.10 Moreover, altered drug exposure as a result of
impaired transport function depends on the remaining excretion
routes, such as complementary efflux transporters on the same
membrane (e.g., canalicular excretion into bile) or alternative
efflux transporters on the opposite membrane (e.g., basolateral
excretion into sinusoidal blood). Thus, in vitro and in vivomodels
to assess changes in hepatocellular accumulation and routes of
excretion of compounds in the setting of impaired transport
function are greatly needed.
Several model systems have been proposed to assess the role of
BCRP andMRP2 in the disposition of a substrate. One approach
is the use of specific BCRP and MRP2 inhibitors in hepatocytes.
However, inhibitors of BCRP (e.g., GF120918, Ko134,
fumitremorgin C, mitoxantrone, novobiocin) and MRP2 (e.g.,
MK-571, benzbromarone) may not be specific enough to allow
assessment of the role of individual proteins.11−13 Similarly,
specific substrates have been employed in hepatocytes and
transport protein overexpressing cells to evaluate quantitatively
the contribution of an individual hepatic uptake transporter [i.e.,
relative activity factor (RAF) method],14 but “specific” BCRP
and MRP2 substrates are lacking due to the aforementioned
overlapping substrate spectrum of these transport proteins.
Although the use of transient or stably transfected cell lines
expressing one or more transport proteins is a popular approach
to assess the role of individual proteins in substrate disposition,
this approach may be misleading. Expression levels of transport
proteins in these in vitro systems may not be representative of the
true physiologic state, and metabolic systems as well as other
regulatory factors impacting hepatobiliary disposition of
substrates may be absent or present at low levels, depending
on the in vitro system. Thus, transport of substrates by a specific
protein in transporter-expressing cells in vitro does not guarantee
that the transporter will play a key role in substrate disposition in
vivo.
Another approach is the use of naturally occurring, genetically
deficient rodents or genetically engineered animals lacking a
specific transport protein. Mrp2-deficient Wistar (TR−) rats and
Eisai-hyperbilirubinemic Sprague−Dawley rats have been used
to delineate the role of Mrp2 in drug disposition in vivo.15,16
Likewise, Bcrp knockout (Abcg2−/−) mice have been used to
investigate whether Bcrp is involved in the disposition of drugs
such as RSV, methotrexate, mitoxantrone, and pitavasta-
tin.8,17−19 Recently, Mrp2 knockout rats and Bcrp knockout
rats were generated using zinc finger nuclease technology, and
knockout phenotypes in these rats were characterized using
sulfasalazine and 5-(and 6)-carboxy-2′,7′-dicholorofluorescein as
probes for Bcrp and Mrp2 function, respectively.20,21 While in
vivo pharmacokinetic studies in these models provide insight
regarding overall drug distribution and excretion, sandwich-
cultured hepatocytes (SCH) prepared from rodents lacking a
specific transport protein allow assessment of altered hepato-
biliary disposition in isolation from other organs.22−24
RNA interference (RNAi) is one approach to explore the
consequences of impaired protein function, and has been used to
knock down transport proteins in the SCH system. Tian et al.
transfected rat SCH with synthetic small interfering RNA
(siRNA) to specifically knock down protein levels of Mrp2 and
Mrp3; approximately 50% knockdown was achieved using this
approach.25 Knockdown of mRNA and protein levels of
OATP1B1, OATP1B3, and OATP2B1 using siRNA has been
reported in human SCH.26 In primary cells, it is technically
challenging to reach high transfection efficiency. Delivery of
short hairpin (sh) RNA using an adenoviral vector system
resulted in high infection efficiency leading to high knockdown
efficiency.27 Rat SCH infected with adenoviral vectors expressing
shRNA targeting Bcrp exhibited a significant decrease in protein
expression and activity of this canalicular transport protein; the
disposition of digoxin, a P-gp substrate, and the expression of
some other transport proteins was not affected.28
To date, primary hepatocyte models lackingmultiple transport
proteins have not been established. Such a model may be of
particular importance if it mimics the physiological condition
when an administered drug inhibits the function of multiple
transporters due to the nonspecific nature of transport inhibitors.
The purpose of this investigation was to develop an in vitromodel
system to assess the consequences of altered transport function
when multiple proteins are involved in hepatic excretion.
Knockdown of Bcrp in SCH from TR− and wild-type (WT)
rats was developed as an in vitro system to assess the impact of
impaired function of Bcrp and/or Mrp2 using probe substrates.
RSV, a Bcrp andMrp2 substrate, and taurocholate (TC), a model
bile acid that is not transported by Bcrp and Mrp2, were selected
as probe substrates for investigation. This report describes a two-
stage statistical analysis strategy for optimizing the knockdown
system.
■ EXPERIMENTAL METHODS
Chemicals. Penicillin−streptomycin solution, dexametha-
sone, Hanks’ balanced salt solution (HBSS; with or without Ca2+
and Mg2+), collagenase (type IV), and Triton X-100 were
purchased from Sigma-Aldrich (St. Louis, MO). Dulbecco’s
modified Eagle’s medium (DMEM) and MEM nonessential
amino acids were purchased from Invitrogen (Carlsbad, CA).
Insulin/transferrin/selenium culture supplement, BioCoat cul-
ture plates, and Matrigel extracellular matrix were purchased
from BD Biosciences Discovery Labware (Bedford, MA).
[3H]TC (5 Ci/mmol; purity >97%) and [3H]E217G (50.3 Ci/
mmol; purity >97%) were purchased from Perkin-Elmer
(Waltham, MA). [3H]RSV (10 Ci/mmol; purity >99%) was
purchased from American Radiolabeled Chemicals (St. Louis,
MO). All other chemicals and reagents were of analytical grade
and were readily available from commercial sources.
Packaging of Recombinant shRNA-Expressing Adeno-
viral Vectors. Adenoviral vectors expressing small hairpin RNA
(shRNA) targeting rat Bcrp (Ad-siBcrp), rat Mrp2 (Ad-siMrp2)
or a nontargeted control shRNA (Ad-siNT) were packaged as
published previously using the Adeno-XTM ViralTrak DsRed-
Express Promoterless Expression System 2 (Clontech Labo-
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ratories, Mountain View, CA).28 The titer of adenoviral vectors
was measured using Adeno-X Rapid Titer Kit (Clontech
Laboratories, Mountain View, CA). siRNA sequences targeting
the rat Bcrp gene at positions 288−306 relative to the start codon
were published previously;28 siRNA sequences targeting rat
MRP2 at positions 4257−4275 and a nontarget siRNA (Ad-
siNT) control sequence (ATGTATTGGCCTGTATTAG)
were obtained from Darmacon (Chicago, IL).
Isolation and Culture of Rat SCH. Primary rat hepatocytes
were isolated from male Wistar (220−300 g, Charles River
Laboratories, Inc., Wilmington, MA) and TR− (220−300 g, bred
in-house; breeding stock obtained from Dr. Mary Vore,
University of Kentucky, Lexington, KY) rats and seeded onto
24-well collagen-coated plates at a density of 0.35 × 106 cells/
well in seeding medium (DMEM containing 5% fetal bovine
serum, 10 μM insulin, 1 μM dexamethasone, 2 mM L-glutamine,
1% MEM nonessential amino acids, 100 units of penicillin G
sodium, and 100 μg of streptomycin). One hour after seeding,
hepatocytes were infected with Ad-siBcrp, Ad-siMrp2, or Ad-
siNT at multiplicity of infection (MOI) of 1, 3, 5, and 10 by
replacing the seeding medium with fresh seeding medium
containing virus. On the next day, media including viruses was
removed, and cells were overlaid withMatrigel at a concentration
of 0.25 mg/mL in 0.5 mL/well ice-cold culture medium (DMEM
supplemented with 0.1 μM dexamethasone, 2 mM L-glutamine,
1% MEM nonessential amino acids, 100 units of penicillin G
sodium, 100 μg of streptomycin, and 1% insulin/transferrin/
selenium). Culture medium was changed every 24 h until
experiments were performed on day 4.
Quantitative Real-Time Polymerase Chain Reaction
(RT-PCR). Total RNA was isolated from cell lysates using the
ABI RNA isolation system (Applied Biosystems, Foster City,
CA). mRNA levels of rat Bcrp and β-actin (internal control) were
measured by TaqMan real-time RT-PCR using an ABI Prism
7700 System (Applied Biosystems) as described previously.29
The TaqMan probe and primer sequences (5′−3′) used for rat
Bcrp were as follows: forward (TGGATTGCCAGGCGTTC-
ATT), reverse (GTCCCAGTATGACTGTAACAA), and probe
(CTGCTCGGGAATCCTCAAGCTTCTG). Rat β-actin was
detected using the following probe and primer sequences:
forward (TGCCTGACGGTCAGGTCA), reverse (CAGGAA-
GGAAGGCTGGAAG), and probe (CACTAATCGGCAATG-
AGCGGTTCCG). Fold changes in mRNA levels of Bcrp were
evaluated after normalizing the gene expression levels by those of
β-actin (2−ΔΔCt method) as previously described.30
Immunoblots.Cells were washed with HBSS and lysis buffer
containing 1% NP-40, 0.1% Na+-deoxycholate, 1 mM EDTA,
and complete protease inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany) was applied. Protein concentrations were
measured by the BCA assay (Pierce, Rockford, IL). Whole-cell
lysates (15 μg) were resolved on NuPAGE 4 to 20% Bis-Tris gel
(Invitrogen, Carlsbad, CA), and the proteins were transferred to
nitrocellulose membranes. After blocking in 5% nonfat milk in
Tris-buffered saline with Tween 20 (TBST) for 30 min, blots
were incubated overnight at 4 °C with the following antibodies:
Bcrp (BXP-53), Mrp2 (M2III-6), Mrp4 (M4I-10), and P-gp
(C219) (Alexis Biochemicals, San Diego, CA); Oatp1a1
(AB3570P, Millipore, Billerica, MA); Bsep (K44, kind gift
from Drs. Bruno Stieger and Peter Meier); and β-actin (C4,
Chemicon, San Francisco, CA). After incubation with HRP-
conjugated secondary antibody, signals were detected by
chemiluminescent substrate Supersignal West Duro (Pierce,
Rockford, IL) with a Bio-Rad VersaDoc imaging system;
densitrometry analysis was performed using Quantity One
V4.1 software (Bio-Rad Laboratories, Hercules, CA).
Accumulation Studies in Rat SCH. Accumulation studies
were conducted in SCH on day 4 as described previously.31
Briefly, cells were washed twice with 0.3 mL of warm standard
(Ca2+-containing) or Ca2+/Mg2+-free HBSS with 0.38 g/L
EGTA (hereafter referred to as Ca2+-free) and incubated in the
same buffer for 10 min at 37 °C to maintain or disrupt tight
junctions, respectively. Subsequently, cells were incubated at 37
°C for 10 min with 0.25 mL of standard HBSS containing
[3H]TC, [3H]RSV, or [3H]E217G at 1 μM (100 nCi/mL). After
10 min, cells were washed 3× with ice-cold standard HBSS and
lysed with 0.25 mL of 0.5% (v/v) Triton X-100 in phosphate-
buffered saline. Samples were quantified by a Tri-Carb 3100 TR
liquid scintillation analyzer (Perkin-Elmer, Waltham, MA).
Transport function was normalized to the protein content of
each preparation using the BCA protein assay. The biliary
excretion index (BEI; %) was calculated using B-CLEAR
technology (Qualyst Transporter Solutions, Research Triangle










Experimental Design. SCH were obtained from n = 3 WT
rats and n = 3 TR− rats. From each rat, sets of 3 SCH samples
(“triplicates”) were systematically assigned by plate location to
each of the 36 combinations of virus (Ad-siBcrp, Ad-siNT,
noninfected), MOI (1, 3, 5, 10), and evaluation procedure (RT-
PCR, immunoblots, RSV accumulation, TC accumulation, as
noted in Figures 1, 2, 3). For each level of MOI, triplicates were
assigned to the three levels of virus (Ad-siBcrp, Ad-siNT,
noninfected) in ratios of 1:1:1. For RT-PCR and immunoblot
assays, two of the triplicate samples were measured, which
provided 2 numerical assay values that were averaged together as
a preliminary step for statistical analysis. For the accumulation
studies of probe substrates, triplicate samples provided 3
numerical assay values that were averaged together as a
preliminary step for statistical analysis. MOI of 1 was
intentionally not studied by RT-PCR and immunoblots;
otherwise, the experimental design produced complete data
(i.e., no missing values for any assays).
Auxiliary Experimental Designs. Preliminary experimen-
tation briefly explored two alternatives to the recommended
knockdown system: (1) a system using Ad-siMrp2 for knock-
down as an alternative to relying on TR− rat SCH, and (2) a
system using Ad-siBcrp with Ad-siMrp2 for double-knockdown.
SCH obtained from n = 4 WT rats were systematically assigned
to selected combinations of three factors: virus (Ad-siMrp2, Ad-
siBcrp with Ad-siMrp2, Ad-siNT, noninfected), MOI (5, 10, 15,
20), and evaluation procedure (RT-PCR, immunoblots, probe
accumulation). Intentionally, the combinations studied were
assigned to either triplicate or duplicate sets of SCH samples
from 2, 3, or 4 rats (as noted in Supplement Figures 1, 2, and 3 in
the Supporting Information); otherwise, the design produced
complete data (i.e., no missing values for the assays.)
Two-Stage Statistical Analysis Strategy. The “dose-
finding” analyses of stage 1 (Figures 1, 2, 3) explored the dose−
response relationship between MOI and measures of the
resulting on-target and off-target effects. For the MOI “dose”
selected as optimal, stage 2 (Table 1) summarized for each of two
probes, RSV and TC, the effects of suppressing Bcrp and/or
Mrp2 function. Stages 1 and 2 illustrate proposed approaches for
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MOI selection and characterization of the effects of impaired
transporter function on the disposition of compounds of interest.
In stage 1, the extent of Bcrp knockdown (Figure 1) was
evaluated in terms of Bcrp mRNA expression, and separately in
terms of Bcrp protein: the primary inferential analysis of Bcrp
expression relied on a univariate repeated-measures analysis of
variance model (unirep-ANOVA) assuming that mean ex-
pression was a function of seven categories defined by virus
[Ad-siBcrp, Ad-siNT, and noninfected (MOI = 0 only)] and
MOI (3, 5, 10 for Ad-siBcrp and Ad-siNT). The model was fit to
the TR− rat SCH data, and separately to the WT rat SCH data
yielding statistical estimates of mean expression [with 95%
confidence intervals (CIs)], residual variance, and within-rat
correlation. The extent of Bcrp knockdown was defined by the
three mean differences between Ad-siBcrp infected (MOI = 3, 5,
10) and noninfected (MOI = 0) SCH. The null hypothesis “all
three differences are exactly zero” was rejected if any of the three
subhypotheses were rejected by the (modified-Bonferroni)
Hochberg test procedure (α = 0.05). The same strategy was
applied to similar hypothesis tests regarding Ad-siNT. The
graphical summary was computed in terms of relative expression;
specifically, the values for each rat type (WT or TR−) were
expressed as a percent of the average that was observed in that
noninfected SCH samples.
Continuing stage 1, potential off-target knockdown (Figure 2)
was explored for a selection of six other proteins (Oatp1a1, Ntcp,
Bsep, P-gp, Mrp4, and Mrp2) using the same graphical summary
method and the same inferential analysis methods that were
applied to Bcrp protein expression. For each protein, the unirep-
ANOVAmodel was used to obtain point and confidence interval
estimates of mean expression as a function of five categories
defined by virus [Ad-siBcrp, Ad-siNT, and noninfected (MOI = 0
only)] and MOI (5, 10 for Ad-siBcrp and Ad-siNT). The
hypothesis testing strategy was as described above for Bcrp
protein.
Completing stage 1, the dose−response relationship (Figure
3) betweenMOI and disposition of RSV and TC was explored in
terms of total substrate accumulation (uptake in pmol/mg of
protein) and biliary excretion index (BEI %). The analysis relied
on a unirep-ANOVA model assuming that the mean was a
function of nine categories defined by virus [Ad-siBcrp, Ad-siNT,
and noninfected (MOI = 0 only)] and MOI (1, 3, 5, 10 for Ad-
siBcrp and Ad-siNT). The model was fit to the TR− rat SCH
data, and separately to the WT rat SCH data, yielding statistical
estimates of mean levels of response (total accumulation and
BEI), residual variance, and within-rat correlation. Estimates of
mean response (individual and marginal) and differences among
mean marginal responses were all tabulated together with 95%
CIs. The off-target effects of Ad-siNT were defined by the four
mean differences between Ad-siNT infected (MOI = 1, 3, 5, 10)
and noninfected (MOI = 0) SCH. The null hypothesis “all four
differences are exactly zero” was rejected if any of the four
subhypotheses were rejected by the Hochberg test procedure (α
= 0.05). The targeted effects of siBcrp expression were defined by
the four MOI-specific mean differences between Ad-siBcrp and
Ad-siNT infected SCH. The null hypothesis “all four differences
are zero” was rejected if any of the four subhypotheses were
rejected by the Hochberg test procedure (α = 0.05). The results
from all eight unirep-ANOVA models are summarized in a
graphical illustration (Figure 3).
In stage 2, best estimates (Table 1) of probe effects attributable
to impaired Bcrp function and/or absence ofMrp2 function were
obtained for total substrate accumulation (uptake in pmol/mg of
protein) and BEI (%) using the responses from the SCH samples
that were noninfected compared to those administered virus at
the MOI level selected as optimal “dose”. This stage 2 analyses
relied on a unirep-ANOVA model assuming mean response was
a function of the six categories of virus (Ad-siBcrp, Ad-siNT,
noninfected) and WT or TR− status. For probes RSV and TC,
the resulting estimates of category means, marginal means, and
Figure 1. Efficient knockdown of Bcrp in WT and TR− rat SCH. (A)
Mean relative levels of Bcrp mRNA in SCH samples infected with Ad-
siNT (solid bar) or Ad-siBcrp (open bar) at MOI of 3, 5, and 10. Each
bar represents mean ± SEM of n = 3 rat livers. Duplicate SCH samples
from each liver were analyzed; mRNA levels were expressed as a percent
of the mean for noninfected hepatocytes and averaged together as a
preliminary step for statistical analysis. The hypothesis testing procedure
relied on a univariate repeated-measures ANOVA model for mean
response as a function of MOI and virus. The model was fit separately to
WT and TR− rat SCH data. (B) Mean relative levels of Bcrp protein in
SCH samples infected with Ad-siNT (solid bar) or Ad-siBcrp (open
bar) atMOI of 3, 5, and 10. Representative blots from three independent
studies are shown. β-Actin was used as the loading control for each blot.
Each bar represents mean ± SEM of n = 3 rat livers. Duplicate SCH
samples from each liver were analyzed; protein levels were expressed as a
percent of the mean for noninfected hepatocytes and averaged together
as a preliminary step for statistical analysis. The hypothesis testing
procedure relied on a univariate repeated-measures ANOVA model for
mean response as a function of MOI and virus. The model was fit
separately to WT and TR− rat SCH data. *, statistically significantly
different from noninfected hepatocytes (p < 0.05).
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contrasts thereof were tabulated with their SEs and 95%CIs. The
null hypothesis tested via an F-test procedure (α = 0.05) included
“effects of the viruses do not depend on WT or TR− status”, “no
difference between the marginal means for WT and TR− rat
SCH”, and “no differences among three virus-specific marginal
means”. If and only if virus effects were detected, then an F-test
procedure (α = 0.05) was performed for the two subhypotheses
regarding marginal means: “off-target effects are zero (siNT vs
noninfected)”, “targeted effects are zero (siBcrp vs siNT)”. The
results from all four unirep-ANOVA models are summarized in
Table 1.
For stages 1 and 2, auxiliary analyses were performed to more
fully explore the data and to evaluate the robustness of the main
results to reasonable perturbations of the statistical modeling
assumptions and methods. For example, in stage 1, unirep-
ANOVA models accounting for all three factors (WT or TR−
status, virus, and MOI) were evaluated and interactions were
explored.
All statistical computations were performed using SAS
software v9.2 (SAS Institute Inc., Cary, NC).
■ RESULTS
Targeted Knockdown of Bcrp in WT and TR− Rat SCH.
Relative to noninfected hepatocytes, mean levels of Bcrp mRNA
(Figure 1A) decreased with increasing MOI of Ad-siBcrp in both
WT and TR− rat SCH. For MOI 10, the mean was only 12% and
6.5% of that in noninfected WT and TR− rat SCH, respectively.
In contrast, Ad-siNT infection had negligible impact on mean
Figure 2. Effects of Bcrp knockdown on relative levels of Oatp1a1, Ntcp, Bsep, P-gp, Mrp4, and Mrp2 proteins in WT and TR− rat SCH infected with
Ad-siNT or Ad-siBcrp. (A) Representative blots from three independent studies are shown. β-Actin was used as the loading control for each blot. Mrp2
was evaluated only in WT SCH because it is not expressed in TR− rat SCH. (B) Each bar represents mean ± SEM of n = 3 rat livers. Duplicate SCH
samples from each liver were analyzed; protein levels after infection with Ad-siNT (solid bar) or Ad-siBcrp (open bar) at MOI of 5 and 10 were
expressed as a percent of the mean for noninfected hepatocytes and averaged together as a preliminary step for statistical analysis. The multiple
hypothesis testing procedure relied on a univariate repeated-measures ANOVAmodel for mean response as a function ofMOI and virus. Themodel was
fit separately to WT and TR− rat SCH data. *, statistically significantly different from noninfected hepatocytes (p < 0.05).
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Bcrp mRNA. Similarly, for Bcrp protein (Figure 1B) the mean
level decreased with increasing MOI of Ad-siBcrp in both WT
and TR− rat SCH relative to noninfected hepatocytes. In WT rat
SCH, the mean decreased by 61%, 66%, and 81% with Ad-siBcrp
at MOI of 3, 5, and 10, respectively. In TR− rat SCH, the mean
decreased by 33%, 65%, and 70%, respectively. In contrast, Ad-
siNT infection had much less impact on the mean level of Bcrp
protein in TR− andWT rat SCH; however, for MOI of 10 inWT,
the mean level was decreased by 47%, suggesting that off-target
(nonspecific) effects of viral infection can exist at high MOI
(≥10) under the conditions of the proposed SCH knockdown
system.
Off-Target Effects of Bcrp Knockdown on the Levels of
Other Transport Proteins. For TR− rat SCH, no off-target
effects were detected for Oatp1a1, Ntcp, Bsep, P-gp, Mrp4, and
Mrp2 proteins at MOI of 5 and 10 (Figure 2). For WT rat SCH,
off-target effects (Ad-siNT vs noninfected) were detected only
for Mrp4 and Mrp2 proteins. Mean levels of Mrp4 protein were
decreased by 30% and 55% with Ad-siNT at MOI of 5 and 10,
and by 55% and 56% with Ad-siBcrp at MOI of 5 and 10,
respectively, relative to noninfected SCH samples. For Mrp2
protein, an off-target effect was statistically significant for Ad-
siNT at MOI of 5, but not at MOI of 10, and not for Ad-siBcrp at
either MOI level.
Effects of Impaired Transporter Function on Probe
Disposition. Based on stage 1 analyses, MOI = 5 was selected as
the optimal “dose” for stage 2 analyses of probes RSV and TC.
Figure 3. Effects of nontargeted and targeted adenoviral infection in WT and TR− SCH at increasing MOI. (A) Total accumulation and (B) biliary
excretion index (BEI) of [3H]rosuvastatin; (C) total accumulation and (D) BEI of [3H]taurocholate. Mean values represent the responses of SCH
preparations from n = 3WT (squares) and TR− (circles) rat livers, respectively, infected with nontargeted (Ad-siNT, closed symbols) or targeted (Ad-
siBcrp, open symbols) adenoviral vectors. Triplicate SCH samples from each liver were measured and averaged together as a preliminary step for
statistical analysis. Estimation of means and differences between means relied on a univariate repeated-measures ANOVAmodel for mean response as a
function of MOI and virus. The model was fit separately to WT and TR− rat SCH data. *, statistically significant off-target effect [siNT vs noninfected
(MOI of 0)]. †, statistically significant targeted effect (siBcrp vs siNT).
Table 1. Total Accumulation and BEI (Mean ± SEM) of Probe Substrates at MOI = 5 vs Noninfected Controla
total accumulation (pmol/mg of protein) biliary excretion index (BEI; %)
WT or TR− status WT or TR− status
viral treatment wild-type TR− LSM wild-type TR− LSM
(A) [3H]Rosuvastatin
noninfected 181 (25) 182 (29) 181 (13) 54.3 (8.2) 24.6 (11.0) 39.4 (4.1)
nontargeted (Ad-siNT) 207 (48) 174 (47) 190 (14) 45.4 (6.6) 17.9 (12.7) 31.7 (4.5)*
Ad-siBcrp 184 (30) 171 (45) 177 (14) 30.8 (7.5) 5.9 (3.0) 18.4 (4.5)*,†
LSM 187 (18) 180 (18) 44.1 (5.8) 15.5 (5.8)#
(B) [3H]Taurocholate
noninfected 27.1 (6.3) 41.7 (11.8) 34.4 (5) 83.1 (5.9) 72.6 (5.5) 77.8 (2.7)
nontargeted (Ad-siNT) 21.2 (5.7) 38.0 (14.3) 29.6 (5)* 78.6 (8.3) 64.5 (9.0) 71.5 (3.0)*
Ad-siBcrp 18.0 (5.6) 31.0 (8.7) 24.5 (5)*,† 80.1 (5.5) 60.6 (3.1) 70.3 (3.0)*
LSM 22.1 (6) 36.9 (6) 79.5 (3.8) 66.9 (3.8)
aMeans were estimated via a univariate repeated-measures ANOVA model. Estimates of marginal means are least squares means (LSM) ± SEM. *p
< 0.05 compared to noninfected. †p < 0.05 compared to nontargeted. #p < 0.05 compared to wild-type.
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RSV Total Accumulation. Mean total accumulation of RSV
was similar in WT and TR− rat SCH, and minimally altered by
viral infection. Stage 1 analyses (Figure 3A) did not detect off-
target effects (siNT vs noninfected), targeted effects (siBcrp vs
siNT), nor any effects with increasing MOI. In stage 2 analysis
(Table 1), targeted and nontargeted effects were not detected in
samples administered virus at the MOI of 5.
RSV BEI. MOI-dependent effects of virus and WT or TR−
status were observed in stage 1 analyses (Figure 3B). For WT rat
SCH, a mean decrease in BEI due to off-target effects (siNT vs
noninfected) was detected at MOI of 5 and 10 only, and a mean
decrease in BEI due to targeted effects (siBcrp vs siNT) was
detected at MOI of 5 and 10 only. For TR− rat SCH, the pattern
of response was similar but no effects were statistically significant.
Stage 2 analyses (Table 1) detected effects for both factors. The
marginal mean for TR− was smaller than for WT rat SCH by
28.6% with 95% CI [5.8, 51.3]. The targeted and nontargeted
effects were statistically significant: relative to noninfected
samples, siNT reduced the marginal mean BEI by 7.8% [3.2,
12.4]; relative to siNT, siBcrp reduced the marginal mean BEI by
13.3% [7.5, 19.1]. The difference in BEI between noninfected
and siBcrp was 21% [16.5, 25.7].
TC Total Accumulation. MOI-dependent effects were found
in stage 1 analyses (Figure 3C): For WT rat SCH, the dose-
dependent off-target effects were statistically significant for MOI
of 3, 5, and 10. For TR− rat SCH, off-target effects were not
detected. For both WT and TR− rat SCH, targeted effects were
statistically significant only for MOI of 10. In stage 2 analyses
(Table 1), focusing on MOI = 5, the marginal means were
decreased by nontargeted and targeted effects: relative to
noninfected samples, siNT reduced the marginal mean by 4.8
pmol/mg of protein [1.9, 7.7]; relative to siNT, siBcrp reduced
the marginal mean by 5.1 pmol/mg of protein [1.4, 8.8]. The
difference between noninfected and siBcrp was 9.9 pmol/mg of
protein [7.0, 12.8].
TC BEI. In stage 1 analyses (Figure 3D) for TR− rat SCH, off-
target effects and targeted effects were statistically significant at
an MOI of 10. In stage 2 analyses (Table 1), an off-target effect
was evident: relative to noninfected samples, siNT reduced the
marginal mean BEI by 6.3% [2.5, 10.1]. The targeted effect was
not detected, as in comparison to siNT, siBcrp reduced the
marginal mean BEI by only 1.2% [−3.7, 6.1]; however, the
difference in BEI between noninfected and siBcrp, 7.5% [3.7,
11.3], was statistically significant. The difference in BEI between
TR− andWT, 12.6% [−2.1, 27.3], was not statistically significant.
Sensitivity Analyses and Exploratory Analyses. The main
results of stage 1 and stage 2 analyses were robust to
perturbations of the modeling assumptions (e.g., variance
homogeneity across WT and TR− rat SCH). In stage 1, a
MOI-by-WT or TR− interaction was observed in 3-factor models
for the analyses of TC BEI (p = 0.0038) and RSV total
accumulation (p = 0.0460); however, inclusion or exclusion of
interactions and commonality assumptions yielded negligible
changes in the main results of interest (data not presented).
Ancillary Study of Knockdown of Mrp2 in WT Rat SCH.
Infection with Ad-siMrp2 decreased mean relative levels of Mrp2
protein by 45%, 79%, and 78% at MOI of 5, 10 and 15,
respectively, compared to noninfected SCH (Supplement Figure
1 in the Supporting Information). Infection with Ad-siNT
decreased the mean by 39% at MOI of 10, suggesting that some
off-target effects may exist for largeMOI. In contrast, Ad-siNT or
Ad-siMrp2 at MOI of 5, 10, and 15 had little influence on the
mean relative level of Bcrp protein.
Mean total accumulation of E217G (Supplement Figure 2A in
the Supporting Information) showed little evidence of targeted
or off-target effects. Mean BEI values for E217G (Supplement
Figure 2B in the Supporting Information) appeared to decrease
slightly with increasing MOI. Mean total accumulation of TC
(Supplement Figure 2C in the Supporting Information) was
decreased by Ad-siNT and Ad-Mrp2 at MOI of 10, suggesting
again that off-target effects become more prevalent at MOI≥ 10.
Mean BEI values for TC (Supplement Figure 2D in the
Supporting Information) were influenced least by viral infection.
Due to the off-target effects on TC total accumulation at an MOI
of 10, anMOI of 5 was selected for the double knockdown study.
Ancillary Study of Double Knockdown of Mrp2 and
Bcrp in WT Rat SCH. To suppress both Mrp2 and Bcrp
(Supplement Figure 3 in the Supporting Information), SCH
were infected with Ad-siNT at MOI of 10, Ad-siMrp2 and Ad-
siBcrp (MOI of 5 each; total MOI = 10), or not infected. The
targeted effects (double knockdown vs Ad-siNT) decreased the
mean relative levels of Mrp2 protein and Bcrp protein by 67%
and 64%, respectively, relative to noninfected control. However,
off-target effects also were observed: Ad-siNT infection at MOI
of 10 decreased the mean levels of Mrp2 protein and Bcrp
protein by 47% and 30%, respectively, relative to noninfected
SCH samples. MOI of 10 also induced off-target effects in Bcrp
knockdown SCH described elsewhere in this report; at MOI =
10, Ad-siNT decreased mean relative levels of Bcrp (Figure 1B)
and Mrp4 (Figure 2) in WT rat SCH, and altered hepatobiliary
disposition of probe substrates [i.e., TC total accumulation in
WT SCH (Figure 3C), RSV BEI in WT SCH (Figure 3B), and
TC BEI in TR− SCH (Figure 3D)].
■ DISCUSSION
Protein knockdown in cultured primary hepatocytes is
challenging because it is difficult to reach high transfection
efficiency using conventional transfection reagents. Our
laboratory previously had established an efficient and specific
Bcrp knockdown system in WT rat SCH in 6-well plates using
adenoviral vectors to deliver shRNA into hepatocytes.28 In the
present study, that work was extended to establish an in vitro
system exhibiting impaired function of multiple specific transport
proteins in the 24-well plate format. Scaling from 6-well to 24-
well plates enabled more efficient use of hepatocytes and other
resources required for the study. Initially, double knockdown of
both Mrp2 and Bcrp was attempted. However, off-target effects
in 24-well rat SCH were noted at the higher MOI required to
knock down multiple transport proteins. Because an MOI of 5
was required for efficient knockdown of each transport protein
(Mrp2 and Bcrp), the combination of two different shRNA
targeting different transport proteins required an MOI of 10, at
which off-target effects were prevalent. Use of a tandem plasmid
vector that expresses two different shRNA to facilitate the
simultaneous double knockdown of genes has been applied in
stable cell lines.32 However, plasmid DNA has low transfection
efficiency into primary hepatocytes,27 and adenoviral vectors that
similarly express tandem expression shRNA are not commer-
cially available. Therefore, efficient double knockdown of
transport proteins using the adenoviral vector approach
necessitated a higher viral load in hepatocytes. In order to
circumvent this problem, Mrp2-deficient TR− rat SCH were
employed in combination with Bcrp knockdown using
adenoviral infection of shRNA targeting Bcrp.
To validate this in vitro system, the impact of Bcrp knockdown
on the hepatobiliary disposition of RSV and TC was examined in
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the absence and presence of functional Mrp2. RSV and TC were
selected as probe substrates because different mechanisms
dominate their hepatocellular uptake and biliary excretion. The
results, for a range of MOI “doses” with multiple viral vectors
(siNT vs siBcrp or siMrp2), demonstrated the importance of
optimizing the system when an RNAi approach is employed to
knock down transport proteins. This approach allows greater
confidence in identification of off-target effects and interactions
among factors that might otherwise have been dismissed as
spurious if evaluated at only one level of MOI. This report
demonstrates the use of a two-stage statistical analysis: stage 1
evaluated targeted and off-target effects for a range of MOI in
order to identify dose−response relationships and select an
optimal MOI “dose” for the system. Stage 2 summarized for each
of two probes, RSV and TC, the effects of impaired Bcrp and/or
Mrp2 function. Results of stages 1 and 2 analyses demonstrated
MOI selection and characterization of the effects of impaired
transporter function on the disposition of compounds of interest.
Since changes in protein levels may not always translate to
changes in protein activity, use of relevant probe substrates
(positive and negative controls; TC and RSV in this study) to
assess changes in protein activity is strongly recommended.
The MOI of 5 was chosen as the “dose” for use in stage 2
analyses of the relative contributions of Mrp2 and Bcrp to the
hepatobiliary disposition of the probe substrates. The main
considerations in choosing the optimal MOI “dose” were the
MOI-dependent patterns of targeted and off-target effects
observed in stage 1. For example, targeted effects on RSV BEI
were observed at MOI of 5 and 10. In analysis of total
accumulation of TC, off-target effects were evident at MOI of 3,
5, and 10. At MOI of 10, off-target effects were maintained or
increased based on immunoblots and TC BEI. These data
suggest that an MOI of 5 is a better choice than an MOI of 3 or
10.
In stage 1 analyses, some evidence of interactions between
MOI and WT or TR− status were observed in auxiliary unirep-
ANOVA models for TC BEI and RSV total accumulation. Such
interactions are biologically plausible because loss of Mrp2
function (as in TR− rats) may alter the regulatory machinery of
the cell due to accumulation of endogenous substances such as
bilirubin and bile acid conjugates. This study is consistent with
the premise that altered function of individual transport proteins
does not occur in isolation. Rather, as a result of overlapping
substrate specificity and reliance on multiple mechanisms for
vectorial transport from blood to bile, a complex network of
cellular regulation is perturbed along with transport function,
leading to compensatory changes. If so, it is advantageous to use
an organ-specific in vitro model system, such as SCH, which
recapitulates the relevant disposition, regulatory mechanisms,
and interplay expected in vivo.
At MOI of 5, viral infection had minimal effects on RSV total
accumulation. The nontargeted effect (siNT vs noninfected)
statistically significantly decreased the mean BEI of RSV, and the
targeted effect (siBcrp vs siNT) further reduced the mean BEI of
RSV, consistent with the statistically significant mean decrease in
Bcrp protein attributed to siBcrp. Mean BEI of RSV was
decreased further by TR− status, suggesting an additive effect of
targeted Bcrp knockdown and loss of Mrp2 function. Since Bcrp
expression and function are decreased significantly in TR− rat
SCH,33 reduced RSV BEI in Bcrp knockdown TR− rat SCH
resulted from the combined effects of lack of Mrp2, an inherent
decrease in Bcrp expression, and targeted knockdown of Bcrp.
This is consistent with the known role of Bcrp and Mrp2 in the
biliary excretion of RSV in vivo in rats.17
For TC, mean total accumulation and mean BEI values were
decreased after viral infection relative to noninfected hepato-
cytes. TC is a bile acid that is not transported by Bcrp and Mrp2.
This finding may be attributed to off-target effects of viral
infection on uptake and efflux pathways involved in the
hepatobiliary disposition of bile acids. If so, Ntcp function or
Bsep function might also be altered by viral infection. Although
the immunoblot analysis failed to detect off-target effects for
Ntcp and Bsep proteins, this system should be used with caution
when testing the hepatobiliary disposition of Ntcp and/or Bsep
substrates. Since RSV is transported by humanNTCP, but not by
rat Ntcp,34 RSV uptake was not influenced by potential off-target
effects on Ntcp function in this system.
Viral infection appeared to exert differential off-target effects
on individual transport proteins. Mean levels of Mrp4 protein
were decreased in siNT- and siBcrp-infected hepatocytes at MOI
of 5 and 10. Viral infection also decreased mean levels of Mrp2
protein in siNT-infected rat SCH, whereas off-target effects of
viral infection were not detected on other transport proteins.
Notably, off-target effects onMrp4 were observed inWT, but not
in TR− SCH. Mrp4 is known to be induced by constitutive
androstane receptor (CAR),35 which is activated by bilirubin and
bile acids.36,37 Thus, it is plausible that accumulation of organic
anions such as bilirubin and bile acids in TR− rat hepatocytes due
to lack of Mrp2 prevents viral infection-mediated down-
regulation of Mrp4 through nuclear receptor regulation.
However, further studies are needed to investigate the
mechanism(s) of differential downregulation of Mrp4 in WT
and TR− rats. RSV undergoes biliary and basolateral efflux to a
quantitatively similar extent; MRP4 contributes to basolateral
efflux of RSV.38 However, RSV total accumulation was not
altered by decreased Mrp4 protein expression in siNT- and
siBcrp-infected WT rat SCH, suggesting minimal changes in
Mrp4 function or the presence of other basolateral efflux
transport proteins that can compensate for impaired Mrp4
function.
Recombinant adenovirus has been used widely as a gene
delivery vector because of its high infection efficiency and high
transgene capacity compared to other viral vector systems (i.e.,
lentivirus, retrovirus).27 Thus, it provides a useful tool to deliver
siRNA to primary cells, for which gene delivery is challenging.
Recently, Hollingshead et al. reported a high-throughput gene
silencing method in mouse SCH using transfection reagents.39
To increase transfection efficiency, a “reverse” transfection
method was employed that initiated the transfection of
suspended hepatocytes prior to plating. This approach resulted
in a significant decrease in mRNA levels of Cyp3a11/13.
Although this approach provides a high-throughput method for
functional studies, the expression and function of proteins-of-
interest, as well as potential off-target effects, need to be
investigated further.
There is increasing evidence that membrane transport proteins
play an important role in the pharmacokinetics of many drugs.
Effects of altered function of uptake transporters often are
reflected in systemic drug exposure. However, it is more
challenging to assess the consequences of altered function of
efflux transporters because changes in cellular (e.g., hepatocyte)
exposure, which may be important in predicting efficacy and
toxicity, may not lead to changes in systemic exposure.40−42 The
SCHmodel is an experimental tool that retains hepatic transport
and metabolic capabilities, and provides information about
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hepatic exposure (intracellular concentration), systemic expo-
sure (medium concentration), and biliary excretion (BEI, biliary
clearance) in isolation from other organs. The current study
assessed the utility of RNAi in SCH from hepatocytes lacking
specific transport proteins (e.g., Mrp2-deficient TR− rat
hepatocytes), as an in vitro tool to predict altered accumulation
or disposition of drugs when multiple efflux transporters are
impaired. This approach requires initial efforts for optimization,
but once optimized, it has potential utility for rapid screening of a
number of compounds. Concerns regarding possible off-target
effects should be addressed further with validation of the system
using additional compounds. Recently, Mrp2- and Bcrp-
knockout rats have been shown to possess modest compensatory
changes in expression of ADME-related genes, providing a useful
in vivo system to explore the contribution of these transporters to
drug disposition.43 However, results obtained from preclinical
species may not necessarily translate to humans because of
species differences in transport protein expression, regulation,
and function. To address this question, RNAi also can be applied
to human SCH and future technologies in development (e.g.,
induced pluripotent stem cells, bioengineered culture systems
such as HepatoPac and the Liver Chip) to assess species
differences in transporter function and altered drug disposition.
However, for knockdown of multiple transport proteins in
human SCH, alternative approaches (e.g., tandem plasmid vector
that can express two different siRNA in one vector) should be
developed to minimize potential off-target effects.
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